226 related articles for article (PubMed ID: 27572070)
1. Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.
Moriarty PM; Parhofer KG; Babirak SP; Cornier MA; Duell PB; Hohenstein B; Leebmann J; Ramlow W; Schettler V; Simha V; Steinhagen-Thiessen E; Thompson PD; Vogt A; von Stritzky B; Du Y; Manvelian G
Eur Heart J; 2016 Dec; 37(48):3588-3595. PubMed ID: 27572070
[TBL] [Abstract][Full Text] [Related]
2. Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial.
Moriarty PM; Parhofer KG; Babirak SP; deGoma E; Duell PB; Hohenstein B; Ramlow W; Simha V; Steinhagen-Thiessen E; Thompson PD; Vogt A; von Stritzky B; Du Y; Manvelian G
J Clin Lipidol; 2016; 10(3):627-34. PubMed ID: 27206951
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher.
Ginsberg HN; Rader DJ; Raal FJ; Guyton JR; Baccara-Dinet MT; Lorenzato C; Pordy R; Stroes E
Cardiovasc Drugs Ther; 2016 Oct; 30(5):473-483. PubMed ID: 27618825
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
[TBL] [Abstract][Full Text] [Related]
5. Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.
Santos RD; Wiegman A; Caprio S; Cariou B; Averna M; Poulouin Y; Scemama M; Manvelian G; Garon G; Daniels S
JAMA Pediatr; 2024 Mar; 178(3):283-293. PubMed ID: 38315470
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.
Kastelein JJ; Robinson JG; Farnier M; Krempf M; Langslet G; Lorenzato C; Gipe DA; Baccara-Dinet MT
Cardiovasc Drugs Ther; 2014 Jun; 28(3):281-9. PubMed ID: 24842558
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial.
Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS
J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561
[TBL] [Abstract][Full Text] [Related]
8. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
Dufour R; Hovingh GK; Guyton JR; Langslet G; Baccara-Dinet MT; Din-Bell C; Manvelian G; Farnier M
J Clin Lipidol; 2019; 13(1):138-147. PubMed ID: 30591415
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
[TBL] [Abstract][Full Text] [Related]
10. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.
Kastelein JJ; Ginsberg HN; Langslet G; Hovingh GK; Ceska R; Dufour R; Blom D; Civeira F; Krempf M; Lorenzato C; Zhao J; Pordy R; Baccara-Dinet MT; Gipe DA; Geiger MJ; Farnier M
Eur Heart J; 2015 Nov; 36(43):2996-3003. PubMed ID: 26330422
[TBL] [Abstract][Full Text] [Related]
11. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
12. From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients.
Zenti MG; Altomari A; Lupo MG; Botta M; Bonora E; Corsini A; Ruscica M; Ferri N
Eur J Prev Cardiol; 2018 Nov; 25(17):1843-1851. PubMed ID: 30058841
[TBL] [Abstract][Full Text] [Related]
13. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial.
Stein EA; Gipe D; Bergeron J; Gaudet D; Weiss R; Dufour R; Wu R; Pordy R
Lancet; 2012 Jul; 380(9836):29-36. PubMed ID: 22633824
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study.
Kereiakes DJ; Robinson JG; Cannon CP; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM
Am Heart J; 2015 Jun; 169(6):906-915.e13. PubMed ID: 26027630
[TBL] [Abstract][Full Text] [Related]
15. Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.
Henry RR; Müller-Wieland D; Taub PR; Bujas-Bobanovic M; Louie MJ; Letierce A; Ginsberg HN
Diabetes Obes Metab; 2018 Jul; 20(7):1632-1641. PubMed ID: 29493859
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial.
Cannon CP; Cariou B; Blom D; McKenney JM; Lorenzato C; Pordy R; Chaudhari U; Colhoun HM;
Eur Heart J; 2015 May; 36(19):1186-94. PubMed ID: 25687353
[TBL] [Abstract][Full Text] [Related]
17. Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia.
Ginsberg HN; Tuomilehto J; Hovingh GK; Cariou B; Santos RD; Brown AS; Sanganalmath SK; Koren A; Thompson D; Raal FJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):69-76. PubMed ID: 30734207
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial.
Taskinen MR; Del Prato S; Bujas-Bobanovic M; Louie MJ; Letierce A; Thompson D; Colhoun HM
Atherosclerosis; 2018 Sep; 276():124-130. PubMed ID: 30059843
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study.
Stroes E; Guyton JR; Lepor N; Civeira F; Gaudet D; Watts GF; Baccara-Dinet MT; Lecorps G; Manvelian G; Farnier M;
J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27625344
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of alirocumab in Korean patients with hypercholesterolemia and high cardiovascular risk: subanalysis of the ODYSSEY-KT study.
Nam CW; Kim DS; Li J; Baccara-Dinet MT; Li I; Kim JH; Kim CJ
Korean J Intern Med; 2019 Nov; 34(6):1252-1262. PubMed ID: 30257549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]